New findings from the DIGIT-HF trial show low-dose digitoxin can reduce the risk for hospitalization and all-cause mortality in patients with symptomatic heart failure. The results, presented at the ...
The therapeutic efficacy of the cardiac glycoside digitoxin in patients with heart failure and reduced ejection fraction is not established. In this international, double-blind, placebo-controlled ...
MADRID, Spain—Adding digitoxin, a cardiac glycoside, to contemporary guideline-directed medical therapy (GDMT) improves clinical outcomes in patients who have heart failure with reduced ejection ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results